Stay updated on Tagraxofusp in CD123+ AML Clinical Trial
Sign up to get notified when there's something new on the Tagraxofusp in CD123+ AML Clinical Trial page.

Latest updates to the Tagraxofusp in CD123+ AML Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedThe page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference1.0%
- Check34 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for January 30, 2025, while a date for March 25, 2025, has been removed.SummaryDifference1.0%
- Check77 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check92 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check99 days agoChange DetectedThe website has been updated to reflect the termination of the recruiting process due to poor enrollment, with the latest revision being v2.14.2.SummaryDifference1%
Stay in the know with updates to Tagraxofusp in CD123+ AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tagraxofusp in CD123+ AML Clinical Trial page.